Roche Diabetes Care and Mysugr expand their association to increase access to digital health solutions for people with diabetes.
-Users of the MySUGR application can automatically load blood glucose data from next-generation blood glucose meters ACCU-Chek and ACCU-Chek Guide and ACCU-Chek Instant blood methods.
- Users will benefit from improved capabilities to share diabetes data with their health care suppliers and caregivers.
- Health care providers can use Roche's existing tools to achieve better therapeutic decisions in less time and improve their collaboration with patients who are users of the MySugg application.
Basilea, Switzerland, February 15, 2017 - Roche today announced the expansion of its association with Mysugr, a digital diabetes services company that provides applications to help reduce the load of people with diabetes in the treatment of their chronic disease.Integration with the next generation of blood glucose meters ACCU-Chek de Roche and ACCU-Chek Guide and ACCU-Chek Instant systems with the MySugg application allow users to benefit from the association of two different ways: the ability to loadBlood glucose data automatically within the MySugg application and facilitate data shared with health care professionals and caregivers through ACCU-Chek Connect online based on cloud-based online and Emminens Econecta platforms.
The association with Mysugr is compatible with both companies in regards to expanding access to innovative digital health solutions."Thanks to this expanded association we will continue to offer the latest innovations for customers who will grant them power to perfectly integrate the therapy management in their daily lives, so they will have to think and worry less," said Marcel Gmuender, World Roche Diabetes Care."Digital health solutions have shown that they help treat data related to diabetes more effectively. This makes the data more prominent (1) and that they can finally lead to better results for therapy."The extended agreement is effective as of today.
About Rocheroche is the world pioneer in pharmaceutical products and diagnosis centered on the progress of science to improve people's lives.The combined strength of pharmaceutical products and diagnosis under the same roof have made Roche a personalized health care leader - a strategy that aims to fit into the appropriate treatment for each of the patients in the best possible way.
Roche is the largest biotechnological company in the world and has authentically differentiated medications in the areas of oncology, immunology, infectious diseases, ophthalmology and neurosciences.Roche is also the world leader in vitro diagnosis and histological diagnosis of cancer, and is placed at the forefront of diabetes control.
Founded in 1896, Roche continues to seek the best ways to prevent, diagnose and treat diseases and carry out a sustainable contribution to society.The company aims to improve patient access to medical innovations working with important shareholders.29 Developed medications through Roche are included in the World Health Organization Model Lists of Essential Medicines, including antibiotics, antimalars and cancer medicines that save lives.Roche has been recognized as the leading group of the industry within the pharmaceutical, biotechnology and life sciences for eight years in a row through the Dow Jones SustainabilityIndices (DJSI).
The Roche Group, based in Basel, Switzerland, performs activities in more than 100 countries and in 2016 he used more than 94,000 people worldwide.In 2016, Roche invested 9.9 billion Swiss francs at R&D and registered sales of 50.6 billion Swiss francs.Genentech, in the United States, is a complete property member of Roche Group.Roche is the majority shareholder of Pharmaceutical Chugai, Japan.If you want more information visit the website www.roche.com [ Link
About Roche Diabetes Careroche Diabetes Care is a pioneer in the development of blood glucose control systems and a global leader in diabetes control systems and control services.For more than 40 years, the Acu-Chek brand has dedicated itself to allow people with diabetes to live a life as normal and active as possible and help medical care professionals to control the condition of their patients in an optimal way.Today, the ACCU-Chek portfolio offers people with diabetes and professionals innovative products and services and comprehensive solutions for convenient, effective and safe control of diabetes, from the control of blood glucose to the blood control to the information control to theInsulin delivery.The ACCU -Chek brand covers blood glucose meters, infusion pumps, puncture systems, data control and training programs - contributing to an improved medical result.